Clinical Trial

BCMA/CD3 BsAb Therapy for POEMS Syndrome

Name: BCMA/CD3 BsAb Therapy for POEMS Syndrome — clinical trial record (NCT07115654)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA/CD3 bispecific antibody (CM336) in patients with POEMS syndrome.

Trial Details

NCT Number	NCT07115654
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	POEMS Syndrome
Enrollment	10 participants
Start Date	2025-08-10
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-11